Tonix Pharmaceuticals Holding Corp.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.82
- 52-Week Range
- $2.53 – $20.56
- Market Cap
- $49.55M
- P/E (TTM)
- —
- EPS (TTM)
- -12.39
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.24
- PEG Ratio
- —
- Return on Equity
- -84.06%
- Return on Assets
- -47.44%
- Gross Margin
- 89.33%
- Operating Margin
- -436.25%
- Profit Margin
- 0.00%
- Current Ratio
- 4.57
- Debt/Equity
- 0.01
- Total Debt
- $1.25M
- Free Cash Flow
- $-102.01M
- Revenue Growth
- 423.80%
- Earnings Growth
- —
- Enterprise Value
- $-106.74M
Market Snapshot
About
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company developing therapeutics to treat pain, neurologic, psychiatric, and immunologic conditions. The company has a diverse pipeline including product candidates for PTSD, fibromyalgia, Long COVID, and infectious diseases. Tonix also develops vaccines and immunotherapies using proprietary technology platforms.